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The potential to generate both a local and systemic immune response makes the mucosal 
immune system an attractive site for immunization. However, mucosal administration of 
protein and peptide antigens generally results in a poor immune response. Successful mucosal 
vaccination is therefore largely dependent on the development of effective mucosal adjuvants. 
In recent years, many adjuvants and vaccine delivery systems have shown an ability to 
enhance immune responses to mucosally administered antigens. These include bacterially-
derived products such as monophosphoryl lipid A, toxins and immunostimulatory DNA 
sequences. 
 
Cholera toxin consists of a pentameric B oligomer that binds to GM-1 receptors and an 
enzymatically active A subunit that is responsible for the toxicity of this agent. The toxicity of 
the CT holotoxin limits its usefulness as an adjuvant; therefore the cholera toxin B-subunit 
(CTB) which consists only of the non-toxic B-subunit of the cholera enterotoxin is more 
widely used in candidate mucosal vaccines (Goto et al 2000). Fractions prepared from 
Quillaja saponaria (Quil-A) can also be used as adjuvants. Quillaja saponins are known to 
increase the effectiveness of both injected and oral vaccines (Sjolander and Cox 1998). In 
previous studies we have shown that chitosan is able to enhance the effects of other adjuvants 
when administered intranasally (Bramwell et al 1999). In this study we have examined the 
effect of vaginal and rectal administration of diphtheria toxoid in the presence of the 
experimental combination of chitosan plus Quil-A or CTB as a known mucosal adjuvant on 
the systemic and mucosal immune response. 
 
Three groups of five BALB/c mice were immunized via either the rectal or vaginal route (six 
groups in total) with 20μg of diphtheria toxoid in either 30μl of sterile PBS, 0.2% w/v 
chitosan glutamate plus 15μg of Quil-A or 10μg of CTB on day 1, day 7 and day 21. Blood 
samples, vaginal washes and fecal mater were collected on day 14 and 27 and assayed for 
anti-diphtheria specific antibody by indirect ELISA. 
 
The results showed that CTB produced the highest serum IgG response compared to the 
group of mice which received free toxoid or the group of mice which received free toxoid 
with chitosan glutamate plus Quil-A. The group of mice which received diphtheria toxoid 
with chitosan plus Quil-A also showed enhanced systemic IgG responses compared to the 
group of mice which received free toxoid. This trend was the same for either rectal or vaginal 
administration. We are in the process of evaluating the mucosal and cellular responses of 
these groups, but the preliminary results presented in this study clearly show that chitosan 
plus Quil-A can act as an adjuvant for rectally and vaginally delivered antigens. 
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